Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

siRNA Delivery into Tumor Cells by Cationic Cholesterol Derivative-Based Nanoparticles and Liposomes.
In this study, we synthesized new diamine-type cationic cholesteryl carbamate (OH-C-Chol, cholesteryl (2-((2-hydroxyethyl)amino)ethyl)carbamate) and triamine-type carbamate (OH-NC-Chol, cholesteryl (2-((2-((2-hydroxyethyl)amino)ethyl)amino)ethyl)carbamate), and prepared cationic nanoparticles composed of OH-C-Chol or OH-NC-Chol with Tween 80 (NP-C and NP-NC, respectively), as well as cationic liposomes composed of OH-C-Chol or OH-NC-Chol with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (LP-C and LP-NC, respectively) for evaluation of their possible use as siRNA delivery vectors. LP-C and LP-NC/siRNA complexes (lip...
Source: Biological and Pharmaceutical Bulletin - March 8, 2015 Category: Drugs & Pharmacology Authors: Hattori Y, Hara E, Shingu Y, Minamiguchi D, Nakamura A, Arai S, Ohno H, Kawano K, Fujii N, Yonemochi E Tags: Biol Pharm Bull Source Type: research

Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (A). Mechanisms of interaction
Publication date: 15 May 2015 Source:International Journal of Pharmaceutics, Volume 485, Issues 1–2 Author(s): Maksim Ionov , Joanna Lazniewska , Volha Dzmitruk , Inessa Halets , Svetlana Loznikova , Darya Novopashina , Evgeny Apartsin , Olga Krasheninina , Alya Venyaminova , Katarzyna Milowska , Olga Nowacka , Rafael Gomez-Ramirez , Francisco Javier de la Mata , Jean-Pierre Majoral , Dzmitry Shcharbin , Maria Bryszewska This paper examines a perspective on the use of newly engineered nanomaterials as effective and safe carriers of genes for the therapy of cancer. Three different groups of cationic dendrimers (PAMAM, p...
Source: International Journal of Pharmaceutics - March 27, 2015 Category: Drugs & Pharmacology Source Type: research

Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy
Conclusions Human cancer cells responded to repeat siRNA nanoparticles in a similar fashion after a temporary initial alteration and little, if any, resistance was evident against repeated siRNA treatments.
Source: Pharmaceutical Research - November 4, 2015 Category: Drugs & Pharmacology Source Type: research

Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics.
Abstract Recent promising clinical results of RNA therapeutics have drawn big attention of academia and industries to RNA therapeutics and their carrier systems. To improve their feasibility in clinics, systemic evaluations of currently available carrier systems under clinical trials and preclinical studies are needed. In this review, we focus on recent noticeable preclinical studies and clinical results regarding siRNA-based conjugates for clinical translations. Advantages and drawbacks of siRNA-based conjugates are discussed, compared to particle-based delivery systems. Then, representative siRNA-based conjugate...
Source: Advanced Drug Delivery Reviews - October 27, 2015 Category: Drugs & Pharmacology Authors: Lee SH, Kang YY, Jang HE, Mok H Tags: Adv Drug Deliv Rev Source Type: research

Characterization and comparison of two novel nanosystems associated with siRNA for cellular therapy
In this study we developed and characterized two different siRNA NP. On one hand, sorbitan monooleate (Span®80) based NP incorporating the cationic components poly-l-arginine or cationized pullulan, thus allowing the association of siRNA were designed. These NP presented a small size (205nm) and a negative surface charge (−38mV). On the other hand, lipid nanocapsules (LNC) associating polymers with lipids and allowing encapsulation of siRNA complexed with lipoplexes were also developed. Their size was of 82nm with a positive surface charge of +7mV. Both NP could be frozen with appropriate cryoprotectors. Cytotoxicity an...
Source: International Journal of Pharmaceutics - December 13, 2015 Category: Drugs & Pharmacology Source Type: research

Combination Nanopreparations of a Novel Proapoptotic Drug – NCL-240, TRAIL and siRNA
Conclusion These results demonstrate the efficacy of a combination of small-molecule PI3K inhibitors, TRAIL, and siRNA delivered by micellar preparations in multiple cancer cell lines.
Source: Pharmaceutical Research - June 3, 2016 Category: Drugs & Pharmacology Source Type: research

Surface Engineered Dendrimers in Sirna Delivery and Gene Silencing.
CONCLUSION: Thus, surface modified dendrimers render a complete pack which offers increased siRNA loading, increased transfection and permeability, efficient targeting, endosomal escape and protecting siRNA from degradation by RNase and other such enzymes. The objective of this manuscript is to provide different approaches currently available for surface modifications of dendrimers and their overall effect on transfection ability of siRNA to target tissues. PMID: 28292248 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 13, 2017 Category: Drugs & Pharmacology Authors: Tambe V, Thakkar S, Raval N, Sharma D, Kalia K, Tekade RK Tags: Curr Pharm Des Source Type: research

Sustained delivery of siRNA poly- and lipopolyplexes from porous macromer-crosslinked gelatin gels
In this study, we systematically investigated cross-linked gelatin based hydrogel formulations (cGEL) as degradable controlled release matrices for siRNA. Aiming at the definition of correlations between cGEL composition, siRNA nanoparticle formulation, release kinetics of complexed siRNA and transfection efficiency, we combined five different cGEL formulations and three transfection systems, i.e. polyplexes with polyethyleneimine (PEI), PEI in combination with liposomes (lipopolyplexes) and polyplexes based on tyrosin-modified PEI (P10Y). It was found that the distribution of these poly-/lipopolyplexes, when applied onto ...
Source: International Journal of Pharmaceutics - May 9, 2017 Category: Drugs & Pharmacology Source Type: research

Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis
Publication date: 30 August 2017 Source:International Journal of Pharmaceutics, Volume 529, Issues 1–2 Author(s): Xinyan Chen, Yidi Zhang, Chunming Tang, Chunli Tian, Qiong Sun, Zhigui Su, Lingjing Xue, Yifan Yin, Caoyun Ju, Can Zhang The overexpression of survivin in breast cancer cells is an important factor of paclitaxel (PTX) resistance in breast cancer. To overcome PTX resistance and improve the antitumor effect of PTX, we developed a novel liposome-based nanosystem (PTX/siRNA/SS-L), composed of a redox-sensitive cationic oligopeptide lipid (LHSSG2C14) with a proton sponge effect, natural soybean phosphatidylcholin...
Source: International Journal of Pharmaceutics - June 29, 2017 Category: Drugs & Pharmacology Source Type: research

Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics
Publication date: 5 November 2017 Source:International Journal of Pharmaceutics, Volume 532, Issue 2 Author(s): J. Bruniaux, S. Ben Djemaa, K. Hervé-Aubert, H. Marchais, I. Chourpa, S. David The endogenous mechanism of RNA interference is more and more used in research to obtain specific down-regulation of gene expression in diseases such as breast cancer. Currently, despite the new fields of study open up by RNA interference, the rapid degradation of siRNA by nucleases and their negative charges prevent them from crossing cell membranes. To overcome these limitations, superparamagnetic iron oxide nanoparticles (SPIONs) ...
Source: International Journal of Pharmaceutics - October 11, 2017 Category: Drugs & Pharmacology Source Type: research

Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA.
Authors: Capel V, Vllasaliu D, Watts P, Clarke PA, Luxton D, Grabowska AM, Mantovani G, Stolnik S Abstract Despite research efforts full potential of siRNA-based therapeutics has not yet been fully realized due to a need for suitable, effective delivery formulations. Here, we examine a potential of a new class of water-soluble chitosans as siRNA platform for pulmonary delivery. The system is based on piperazine-substituted chitosans, a material designed to integrate established, safe application of chitosan for mucosal administration with novel properties: the piperazine-substituted chitosans are freely water-solub...
Source: Drug Delivery - March 3, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery
Publication date: Available online 21 February 2018 Source:Asian Journal of Pharmaceutical Sciences Author(s): Anna Slita, Anna Egorova, Eudald Casals, Anton Kiselev, Jessica M. Rosenholm Gene therapy using siRNA molecules is nowadays considered as a promising approach. For successful therapy, development of a stable and reliable vector for siRNA is crucial. Non-viral and non-organic vectors like mesoporous silica nanoparticles (MSN) are associated with lack of most viral vector drawbacks, such as toxicity, immunogenicity, but also generally a low nucleic acid carrying capacity. To overcome this hurdle, we here modified t...
Source: Asian Journal of Pharmaceutical Sciences - April 14, 2018 Category: Drugs & Pharmacology Source Type: research

Targeted Delivery of siRNA Therapeutics Using Ligand Mediated Biodegradable Polymeric Nanocarriers.
CONCLUSION: In this review, we provide ⅰ) an overview of the non-viral carrier associated with siRNA delivery for cancer treatment, and ⅱ) a description of the five major cancer-targeting ligands. PMID: 29962332 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - July 1, 2018 Category: Drugs & Pharmacology Authors: Jin HS, Soo CK, Hye AM, Sukdeb P, Pill-Hoon C, Sangshetti J, Arote RB Tags: Curr Pharm Des Source Type: research

Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis.
Abstract The development of an efficient small interfering RNA (siRNA) delivery system has held scientists interest since the discovery of the RNA interference mechanism (RNAi). This strategy gives hope for the treatment of many severe diseases. Herein, we developed hybrid nanovectors able to deliver siRNA to triple negative breast cancer cells. The nanovectors are based on PEGylated superparamagnetic iron oxide nanoparticles (SPION) functionalized with gH625 peptide, chitosan and poly-L-arginine. Every component has a key role and specific function: SPION is the core scaffolding the nanovector; PEG participates i...
Source: European Journal of Pharmaceutics and Biopharmaceutics - July 28, 2018 Category: Drugs & Pharmacology Authors: Ben Djemaa S, David S, Hervé-Aubert K, Falanga A, Galdiero S, Allard-Vannier E, Chourpa I, Munnier E Tags: Eur J Pharm Biopharm Source Type: research

Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma.
In conclusion, prepared DP-CLPs-PTX-siRNA nanocomplex selectively induced CD133+ glioma stem cell apoptosis in vitro and in vivo exhibits great potential for targeted imaging and therapy of brain glioma stem cells. PMID: 30269613 [PubMed - in process]
Source: Drug Delivery - October 3, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research